Research Article
Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study
Table 3
Mean extraction recovery and matrix effects of anlotinib and the IS in rat plasma (n = 6).
| Compound | Concentration (ng/mL) | Extraction recoveries (%) | Matrix effects (%) | Mean ± SD | RSD (%) | Mean ± SD | RSD (%) |
| Anlotinib | 0.25 | 99.32 ± 6.74 | 6.79 | 104.27 ± 3.65 | 3.51 | 5 | 102.27 ± 6.48 | 6.33 | 102.42 ± 4.17 | 4.07 |
| IS | 40 | 104.14 ± 3.95 | 3.8 | 101.33 ± 4.08 | 4.03 | 100 | 106.09 ± 8.11 | 7.65 | 101.66 ± 4.53 | 4.45 |
|
|